TolerRx Raises $31M In Series D To Advance Diabetes Drug TRX4 March 30, 2005 By Karen Carey Less than a year after withdrawing a proposed initial public offering, TolerRx Inc. dipped into the private markets, raising $31 million in a Series D round. (BioWorld Today)Read More
European Regulations On Stem Cell Research Help Limit Risks March 25, 2005 By Karen Carey and Anette Breindl
Coley Gets $50M Up Front In ProMune Alliance With Pfizer March 25, 2005 By Karen Carey Coley Pharmaceutical Group Inc. entered a deal with Pfizer Inc. worth up to $505 million for its lead cancer drug, ProMune. (BioWorld Today)Read More
